Anna Melissa Schlitter Selected Research

Anna Melissa Schlitter Research Topics

Disease

16	Neoplasms (Cancer) 12/2021 - 01/2014
8	Adenocarcinoma 12/2021 - 03/2013
6	Pancreatic Neoplasms (Pancreatic Cancer) 12/2015 - 02/2014
5	Carcinogenesis 01/2021 - 01/2018
4	Neoplasm Metastasis (Metastasis) 12/2021 - 01/2019
3	Pancreatitis 01/2019 - 01/2018
3	Carcinoma (Carcinomatosis) 01/2018 - 01/2014
2	Microsatellite Instability 12/2021 - 09/2021
2	Fibrosis (Cirrhosis) 07/2021 - 07/2018
2	Metaplasia 01/2021 - 03/2013
2	Necrosis 01/2019 - 09/2014
2	Hepatocellular Carcinoma (Hepatoma) 10/2015 - 04/2015
1	Wounds and Injuries (Trauma) 11/2022
1	Colorectal Neoplasms (Colorectal Cancer) 12/2021
1	Lymphoma (Lymphomas) 01/2021
1	Sclerosis 01/2020
1	Esophageal Squamous Cell Carcinoma 12/2019
1	Carcinoid Tumor (Carcinoid) 01/2018
1	Neuroendocrine Carcinoma 01/2018
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2016
1	Tuberous Sclerosis (Bourneville's Disease) 04/2016
1	Exanthema (Rash) 08/2014
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2012
1	Autoimmune Pancreatitis 05/2012

Drug/Important Bio-Agent (IBA)

5	Biomarkers (Surrogate Marker)IBA 12/2021 - 08/2014
3	Proteins (Proteins, Gene)FDA Link 12/2021 - 04/2015
3	RNA (Ribonucleic Acid)IBA 09/2021 - 04/2015
3	Biological ProductsIBA 01/2018 - 01/2014
2	SynaptophysinIBA 12/2021 - 01/2017
2	CollagenIBA 01/2020 - 07/2018
2	CeruletideIBA 01/2019 - 01/2019
2	CytokinesIBA 01/2019 - 01/2019
2	MucinsIBA 07/2018 - 01/2014
2	TOR Serine-Threonine KinasesIBA 04/2016 - 12/2015
2	Sorafenib (BAY 43-9006)FDA Link 10/2015 - 04/2015
2	MicroRNAs (MicroRNA)IBA 07/2015 - 04/2015
2	Piwi-Interacting RNAIBA 07/2015 - 04/2015
1	Hematoxylin (Haematoxylon)IBA 12/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 12/2021
1	Polysaccharides (Glycans)IBA 12/2021
1	LipidsIBA 12/2021
1	N-acetyltalosaminuronic acid (NAT)IBA 07/2021
1	Actin-Related Protein 2-3 Complex (Arp2 3 Complex)IBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2019
1	CathepsinsIBA 01/2019
1	CalciumIBA 01/2019
1	5-Methylcytosine (5 Methylcytosine)IBA 01/2019
1	Toll-Like Receptor 3IBA 01/2019
1	Autophagy-Related Protein 5IBA 01/2019
1	Caspase 8 (Caspase-8)IBA 01/2019
1	ParaffinIBA 01/2019
1	Histones (Histone)IBA 01/2019
1	Interleukin-6 (Interleukin 6)IBA 01/2019
1	LigandsIBA 01/2019
1	Carcinoembryonic AntigenIBA 01/2018
1	Gemcitabine FDA Link 01/2018
1	folfirinoxIBA 01/2018
1	somatostatin receptor 5IBA 01/2017
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2017
1	Keratin-20 (Cytokeratin 20)IBA 01/2017
1	Chromogranin AIBA 01/2017
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2017
1	PeriostinIBA 11/2016
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2016
1	MTOR InhibitorsIBA 04/2016
1	trans-sodium crocetinate (crocetin)IBA 04/2016
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 10/2015
1	NVP-AEW541IBA 04/2015
1	Insulin-Like Growth Factor I (IGF-1)IBA 04/2015
1	Messenger RNA (mRNA)IBA 04/2015
1	Insulin-Like PeptidesIBA 04/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2015
1	Insulin (Novolin)FDA Link 04/2015
1	Indicators and Reagents (Reagents)IBA 09/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2014
1	zolbetuximabIBA 02/2014
1	ClaudinsIBA 02/2014
1	Phosphatidylinositols (Phosphatidylinositol)IBA 03/2013
1	3-Phosphoinositide-Dependent Protein KinasesIBA 03/2013
1	Immunoglobulin G (IgG)IBA 05/2012
1	SteroidsIBA 05/2012

Therapy/Procedure

10	Therapeutics 12/2021 - 10/2014
3	Drug Therapy (Chemotherapy) 04/2020 - 01/2018
1	Lasers (Laser) 11/2022
1	Molecular Targeted Therapy 09/2021
1	Neoadjuvant Therapy 07/2021
1	Ligation 01/2019